

<b>TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT</b>	<b>Docket Number (Optional) ORT 1414USNP</b>
<p>In re Application of: Ning Qin</p> <p>Application No.: 09/833,222</p> <p>Filed: April 11, 2001</p> <p>For: cDNA Encoding the Human Alpha-2 Delta-4 Calcium Channel Subunit</p> <p>The owner*, Ortho-McNeil Pharmaceutical, Inc., of 100 percent interest in the instant application hereby through its attorney disclaims, except as provided below, the terminal part of the statutory item of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of <b>claims 1-3, 11, 12 and 18 of Application No. 10/119,624</b> as the term of said <b>claims</b> are defined in 35 U.S.C. 154 and 173, and as the term of said <b>claims</b> is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the <b>Application No. 10/119,624</b> are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.</p> <p>In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the <b>Application No. 10/119,624</b>, "as the term of said <b>Application</b> is presently shortened by any terminal disclaimer," in the event that said <b>prior patent</b> later:</p> <p style="margin-left: 20px;">             expires for failure to pay a maintenance fee;              is held unenforceable;              is found invalid by a court of competent jurisdiction;              is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;              has all claims canceled by a reexamination certificate;              is reissued; or              is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.         </p> <p>Check either box 1 or 2 below, if appropriate.</p> <p>1. <input type="checkbox"/> For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.</p> <p style="margin-left: 20px;">I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>2. <input checked="" type="checkbox"/> The undersigned is an attorney or agent of record. Reg. No. 47,019.</p> <div style="margin-left: 300px; margin-top: 20px;"> <div style="display: flex; justify-content: space-between; width: 100%;"> <div style="text-align: center;">             _____              /Yunling Ren/              Signature         </div> <div style="text-align: center;">             _____              October 11, 2006              Date         </div> </div> <div style="text-align: center; margin-top: 10px;">             YUNLING REN              Type or printed name         </div> <div style="text-align: center; margin-top: 20px;">             _____              (732) 524-3385              Telephone Number         </div> </div> <p><input type="checkbox"/> Terminal disclaimer fee under 37 CFR 1.20(d) included.</p> <p><small>*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  Form PTO/SB/96 may be used for making this certification. See MPEP § 324.  This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450</small></p> <p>I hereby certify that this correspondence is being <b>electronically transmitted</b> to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:</p> <p>Dated: <u>October 11, 2006</u>      Signature: <u>/Yunling Ren/</u> (YUNLING REN)</p>	